01 Nov 2017
Catalyst Roundup: A review of select catalysts from last quarter's outlook report
Stay on the cutting edge of major market events in drug development. Powered by real-time intelligence, Biomedtracker’s web-based platform tracks and analyzes clinical and regulatory developments so you can quickly and accurately assess a drug's probability of technical success.
How it helps
Biomedtracker's exclusive likelihood of approval analyses highlight the "bottom line" impact of today’s news on your business. Our expert industry analysts draw insights from closely monitoring companies, clinical trials, deals, and regulatory meetings to capture and report on the most critical events.
How it works
Biomedtracker’s intuitive interface features the latest, industry-acclaimed insights, all at your fingertips. We track impactful future catalysts, and then analyze these commercial, clinical, and regulatory activities as they happen, and present them to you via an easily searchable interface that keeps you at the top of your game.
Our analysts attend the medical and investor meetings that matter to you, bringing you not just the news, but vital information on how it impacts your bottom line.
Real-time tracking and analysis of every event in drug development; customized email alerts
Monitor all aspects of the market from one place, from drugs, to targets, to trials, and more
Medical and investor conference planners and post-reports cover major meeting developments
Predict how FDA Panel Members might vote with AdComm Insight
Exclusive likelihood of approval analyses and access to our expert team.
27 Oct 2017
In this report, we cover catalysts from 21 drugs expected to occur in Q4 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.
10 Aug 2017
This free infographic comes to you from Biomedtracker, part of the Informa suite of Pharma Intelligence tools.
Topic Company analysis
17 Jul 2017
In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.
Datamonitor Healthcare, Biomedtracker
14 Jun 2017
Featuring analysts from Informa’s Biomedtracker, Datamonitor Healthcare, and Citeline, the 2017 Informa Pharma Intelligence Post-ASCO Podcast provides commentary into ASCO 2017.
26 May 2017
The 53rd annual meeting of the American Society of Clinical Oncology (ASCO) will be held in Chicago from June 2-6, 2017. This audio-only podcast features Informa Pharma Intelligence analysts Dr. Robert Jeng (Biomedtracker), Dr. David Dahan (Biomedtracker), Dr. Dominique Fontanilla (Datamonitor Healthcare), and Dr. Maria Berezina (Citeline) as they discuss notable abstracts which were released on Wednesday, May 17, 2017.
03 Apr 2017
Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.
23 Mar 2017
There is no doubt that 2016 will be marked as year of surprising results. None more so than how life science companies fared in the capital markets.
Topic Business strategies
Pharmaprojects, Biomedtracker, Trialtrove
By Rachel Meighan-Mantha 22 Mar 2017
The field of epigenetics is rapidly expanding and as interest continues to grow, epigenetics has become an increasingly promising area for research.
28 Feb 2017
Biomedtracker's Early 2017 Outlook Infographic shows the igh Impact Catalysts that will have an effect of the future of the Pharam Industry
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: